Project Grant R01CA288613
Award Date
1/1/25
Completion Date
12/31/29
Dollars Obligated
$593K
Federal Agency
National Cancer Institute
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), provides $1,625,000.00 to Onc.ai, Inc. to develop and validate a radiomics-based multi-modal predictive model for metastatic non-small cell lung cancer patients treated with PD-1 immunotherapy. The key objectives are to: 1) Validate the predictive models in a multi-institutional prospective clinical study, 2) Evaluate the performance characteristics and...
The National Cancer Institute (NCI) awarded a $400,000 Project Grant under CFDA 93.394 (Cancer Detection and Diagnosis Research) to O2M Technologies LLC to develop a Multifunctional Imager (MFI) that can simultaneously acquire tissue oxygen pressure (pO2) and pH maps using electron paramagnetic resonance imaging (EPRI) techniques. The 12-month project aims to create a 25 MT Halbach-type permanent magnet, new multi-modal transmit-receive electronics, and the integrated MFI instrument. This...
This federal Project Grant award of $568,151 from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) supports the development of a real-time functional photoacoustic imaging platform to enable sensitive detection of prostate cancer tumors and accurate characterization of their aggressiveness. The key products and services to be delivered through this 5-year award include: Optimization of biocompatible polyacrylamide hydrogel nanoparticle (PAA NP) probes for...
This $274,594 Project Grant award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program supports research and development of an innovative technology for cancer diagnosis and treatment. The project aims to improve molecular profiling and clinical laboratory testing of cancer samples by optimizing microdissection techniques. The research will focus on modeling and optimizing the opto-thermal-mechanical interactions involved in microdissection to...
The National Cancer Institute (NCI) awarded a $658,336 Project Grant (CFDA 93.394 - Cancer Detection and Diagnosis Research) to Rarecyte, Inc. to develop an "ORION2" instrument that will enable highly multiplexed spatial profiling of tumors and tissues for cancer research and diagnosis. The key products and services to be delivered under this 3-year grant, which runs from June 1, 2025 to May 31, 2028, include: Developing an adaptive imaging system with automated control over...
This $435,827 Project Grant from the National Cancer Institute (NCI) under the CFDA 93.394 Cancer Detection and Diagnosis Research program supports research conducted by New York University (NYU) School of Medicine to develop deep learning methods for analyzing mass spectrometry imaging (MSI) data. The goal is to make MSI data more accessible to existing machine learning workflows by expanding the dimensionality of the data structure to treat each metabolite or lipid as an individual "color...
This $256,000 National Science Foundation Project Grant under the Engineering (47.041) program will support the development of an artificial intelligence-based system for analyzing multiparametric magnetic resonance imaging (MRI) scans to detect prostate lesions. The awardee, Taurus Diagnostics, Inc., will create a novel prostate cancer diagnostic platform leveraging artificial intelligence image analysis for high sensitivity and specificity. Key objectives include developing methods to...
Visikol Inc. received a $4,103,265 Project Grant award from the National Cancer Institute, a division of the Department of Health and Human Services, under the Cancer Detection and Diagnosis Research program (CFDA 93.394). The award will support the development of a 3D imaging diagnostic tool to improve characterization of metastatic melanoma in sentinel lymph node biopsies. Visikol will conduct a retrospective clinical study using archived negative sentinel lymph node biopsy tissue blocks to...
The National Cancer Institute (NCI) awarded a $570,634 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to the University of Connecticut to develop a robust, multimodal, and longitudinal artificial intelligence (AI) system to enhance breast cancer screening. The overarching objective is to optimize and personalize breast cancer screening by advancing AI algorithms that can transform clinical decision-making. The key products/services to be delivered...
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), provides $549,536 to the Trustees of Dartmouth College to develop an innovative 3D wearable near-infrared (NIR) spectral tomography system. The objective is to create a clinical platform capable of early prediction of residual cancer burden in breast cancer patients undergoing neoadjuvant chemotherapy. The proposed technological innovations focus...